Activity of ICI 195,739, a new oral triazole, compared with that of ketoconazole in the therapy of experimental murine blastomycosis.
ICI 195,739, a novel orally active triazole, proved 50 times as potent as ketoconazole, produced a clinical cure, and completely eradicated residual infection in a murine model of pulmonary blastomycosis. No other previously tested azole has shown similar activity. Fungicidal activity against Blastomyces dermatitidis was seen in vitro at concentrations 1/40 of those achieved in serum with protective doses.
Tucker
R M
RM
Department of Medicine, Santa Clara Valley Medical Center and Institute for Medical Research, San Jose, California 95128.
Hanson
L H
LH
Brummer
E
E
Stevens
D A
DA
D000818:Animals; D000935:Antifungal Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001758:Blastomyces / Q000187:drug effects; D001759:Blastomycosis / Q000188:drug therapy* / Q000382:microbiology; D007654:Ketoconazole / Q000627:therapeutic use*; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D013997:Time Factors; D014230:Triazoles / Q000493:pharmacokinetics / Q000627:therapeutic use*
D000935:Antifungal Agents; D014230:Triazoles; C058219:ICI 195739; D007654:Ketoconazole